Bright Green Corporation Share Price

Equities

BGXX

US10920G1004

Pharmaceuticals

Real-time Estimate Cboe BZX 15:01:28 29/04/2024 BST 5-day change 1st Jan Change
0.194 USD -2.81% Intraday chart for Bright Green Corporation -5.98% -39.53%
Sales 2022 - Sales 2023 - Capitalization 60.7M 4.85B
Net income 2022 -27M -2.16B Net income 2023 -13M -1.04B EV / Sales 2022 -
Net Debt 2022 3.66 292.71 Net Debt 2023 0.19 15.32 EV / Sales 2023 -
P/E ratio 2022
-2.75 x
P/E ratio 2023
-4.49 x
Employees 5
Yield 2022 *
-
Yield 2023
-
Free-Float 38.62%
More Fundamentals * Assessed data
Dynamic Chart
1 day-2.81%
1 week-5.98%
Current month-18.06%
1 month-18.06%
3 months-13.22%
6 months-44.26%
Current year-39.53%
More quotes
1 week
0.16
Extreme 0.1584
0.21
1 month
0.16
Extreme 0.1584
0.29
Current year
0.15
Extreme 0.15
0.54
1 year
0.15
Extreme 0.15
1.81
3 years
0.15
Extreme 0.15
58.00
5 years
0.15
Extreme 0.15
58.00
10 years
0.15
Extreme 0.15
58.00
More quotes
Managers TitleAgeSince
Director of Finance/CFO 39 28/02/22
47 -
Members of the board TitleAgeSince
Founder 66 15/04/19
Director/Board Member 51 31/12/19
Director/Board Member 57 30/06/21
More insiders
Date Price Change Volume
25/04/24 0.1996 +8.48% 164 856
25/04/24 0.184 -6.12% 911,567
24/04/24 0.196 -0.86% 185,682
23/04/24 0.1977 -0.20% 342,156
22/04/24 0.1981 -6.69% 500,400

End-of-day quote Nasdaq, April 25, 2024

More quotes
Bright Green Corporation is a provider of cannabis, cannabis-related products, and other legal medicinal plant-based therapies, manufactured in exact formulations for research and pharmaceutical applications and as an active ingredient to consumer-based solutions. The Company is engaged in cannabis propagation, cultivation, and manufacturing of cannabis products, including cannabis flower, pre-rolls, concentrates, vape pens, capsules, tinctures, edibles, topicals and any other cannabis-related products requested for authorized sales. The Company plans to sell extracted oils from medicinal plants grown in these high-tech facilities and processed onsite through a system that vertically integrates the genetically altered growth of the plants to conform to automated growing systems. It also plans to cultivate and manufacture cannabis for federally sanctioned research, as well as perform authorized research on cannabis, including cannabinol (CBN), cannabigerol (CBG), and cannabidiol (CBD).
Related indices
More about the company